Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing

6/10 Pre-Exposure Prophylaxis study (treated before exposed to the virus)

Jehi et al., Chest, doi:10.1016/j.chest.2020.05.580 (Peer Reviewed)
Individualizing Risk Prediction for Positive Coronavirus Disease 2019 Testing

Source PDF Share Tweet

Retrospective 11,672 patients tested for COVID-19, 818 that tested positive, showing significantly lower risk with melatonin use.

Jehi et al., 6/10/2020, retrospective, USA, North America, peer-reviewed, 8 authors.

risk of COVID-19 case, 58.2% lower, RR 0.42, p < 0.001, treatment 16 of 532 (3.0%), control 802 of 11140 (7.2%), development cohort.

risk of COVID-19 case, 99.7% lower, RR 0.003, p = 0.09, treatment 0 of 18 (0.0%), control 290 of 2005 (14.5%), continuity correction due to zero event (with reciprocal of the contrasting arm), Florida validation cohort.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 9 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit